Sumitomo Pharma America, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1253
- Registration Number
- NCT02753127
- Locations
- πΊπΈ
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
πΊπΈDana Farber, Boston, Massachusetts, United States
π¨π¦University of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT02734693
- Locations
- πΊπΈ
Avida Inc, Newport Beach, California, United States
πΊπΈMeridien Research, Bradenton, Florida, United States
πΊπΈBayou City Research, Ltd, Houston, Texas, United States
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
- Conditions
- Recurrent Ovarian CarcinomaColorectal CarcinomaBRAF-Mutated MelanomaAdvanced Solid TumorsEGFR Positive Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02729298
- Locations
- πΊπΈ
HonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈMayo Clinic Florida, Jacksonville, Florida, United States
πΊπΈUS Oncology - Texas Oncology - Fort Worth, Fort Worth, Texas, United States
Dasotraline Binge Eating Disorder Extension Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 533
- Registration Number
- NCT02684279
- Locations
- πΊπΈ
Neuotrials Research, Inc., Atlanta, Georgia, United States
πΊπΈBoston Clinical Trials, Boston, Massachusetts, United States
πΊπΈTexas Center for Drug Development, Inc., Houston, Texas, United States
Dasotraline Binge Eating Disorder Study
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT02564588
- Locations
- πΊπΈ
PCSD- Feighner Research, San Diego, California, United States
πΊπΈCapstone Clinical Research, Libertyville, Illinois, United States
πΊπΈSunstone Medical Research, LLC, Medford, Oregon, United States
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT02542696
- Locations
- πΊπΈ
Keck Medical Center at USC, Los Angeles, California, United States
πΊπΈClinical Trials, Inc., Little Rock, Arkansas, United States
πΊπΈUC Irvine Health Gottschalk Medical Plaza, Irvine, California, United States
An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
- Conditions
- SCAR
- Interventions
- Other: Blood or Saliva
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT02520557
- Locations
- πΊπΈ
University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States
Alvocidib Biomarker-driven Phase 2 AML Study
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02520011
- Locations
- πΊπΈ
Honor Health Research Institute, Scottsdale, Arizona, United States
πΊπΈMayo Clinic Florida, Jacksonville, Florida, United States
πΊπΈMorristown Cancer Center, Morristown, New Jersey, United States
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesGlioblastoma MultiformeMelanomaNon-Small Cell Lung CancerOvarian CancerPancreatic CancerSarcomaRenal Cell Carcinoma
- Interventions
- Drug: DSP-7888 Dosing Emulsion
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02498665
- Locations
- πΊπΈ
Horizon Oncology Research, Lafayette, Indiana, United States
πΊπΈUSOR - TX Oncology Austin, Austin, Texas, United States
πΊπΈUSOR - TX Oncology Tyler, Tyler, Texas, United States
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
- Conditions
- Epilepsy
- Interventions
- Other: blood draw
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02491073
- Locations
- πΊπΈ
Mid-Atlantic Epilepsy Center, Bethesda, Maryland, United States
πΊπΈConsultans in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
πΊπΈMinneapolis Clinic of Neurology, Golden Valley, Minnesota, United States